GSK vs TSLA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 21, 2026
GSK
TSLA
Investment Advisor Scores
TSLA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GSK | TSLA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 20.5339 | 175.4386 | GSK |
| PEG Ratio | 102.7218 | 4.9714 | TSLA |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 5.3% | 25.5% | TSLA |
| Earnings Growth | -69.5% | -3.0% | TSLA |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 54.2/100 | 46.7/100 | GSK |
| Profit Margin | 14.5% | 3.7% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | STRONG BUY | HOLD | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GSK
MarkupPrice above SMA50, rising 50-day trend (0.7% over 20 days), RSI 54
TSLA
NeutralMixed signals - no dominant trend phase, RSI 58
Fundamentals Snapshot
| Metric | GSK | TSLA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 10.2 | 161.4 |
| Trailing P/E | 16.3 | 309.1 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.3% |
| Gross Margin | 0.7% | 0.2% |
| Operating Margin | 0.3% | 0.0% |
| EPS | 3.19 | 1.09 |
| Dividend Yield | 0.04% | — |